Skip to main content

Table 1 Clinical and biological features of SLE and RA patients

From: Polymorphisms of Toll-like receptor-4 and CD14 in systemic lupus erythematosus and rheumatoid arthritis

SLE patients n = 127 RA patients n = 100
Mean Age ± DS (years) 32,48 ± 13,59 Mean age ± DS (years) 40,43 ± 14,48
Median of evolution ± DS (years) 5 ± 4,96 Median of evolution ± DS (months) 120 ± 97,46
Sex ratio (Female/Male) 6,47 (110/17) Sex ratio (Female/Male) 3,54 (78/22)
   Early onset before 40 years 51 (51%)
Cutaneous lesions n (%) 77 (60,6%) Bone erosions n (%) 38 (38%)
Arthritis n (%) 97 (76,3%) Subcutaneous nodules n (%) 17 (17%)
Nephritis n (%) 68 (53,5%)   
Titer of ANA > 1/200 n (%) 106 (83,4%) Rheumatoid factor (RF) n (%) 75 (75%)
Anti-dsDNA antibodies (Abs) n (%) 90 (70,8%) Anti-CCP antibodies (ACCPA) n (%) 73 (73%)
Decreased complement activity (DCA) n (%) 93 (73,2%) HLA-DRB1*04 allele 46 (46%)
   Shared epitope 46 (46%)
SLEDAI* ≥ 8 n (%) 91 (71,6%) Active RA (DAS28† ≥ 5,1) n (%) 70 (70%)
   DAS28† (average ± DS) 5,97 ± 1,72
  1. * SLE disease activity index: a score meant to measure the activity in SLE in patients.
  2. † Disease activity score 28: a score for evaluation of RA activity by assessing the state of 28 joints.
\